Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Sjogren's Disease or Idiopathic Inflammatory Myopathy

NCT07229144 is registered in ClinicalTrials.gov with Lakefront Biotherapeutics West LLC as lead sponsor.

NCT NCT07229144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07229144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Sjogren's Disease or Idiopathic Inflammatory Myopathy
Lead sponsor
Lakefront Biotherapeutics West LLC
Phase
Phase 1
Overall status
Recruiting
Start date
October 1, 2025
Completion date
March 31, 2028
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic inflammatory myopathy (iim), sjogrens disease